NuVasive, Inc. (NASDAQ:NUVA – Get Rating) CEO James Christopher Barry sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $58.00, for a total transaction of $290,000.00. Following the completion of the transaction, the chief executive officer now owns 50,218 shares of the company’s stock, valued at approximately $2,912,644. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
James Christopher Barry also recently made the following trade(s):
- On Monday, March 28th, James Christopher Barry sold 5,000 shares of NuVasive stock. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00.
Shares of NASDAQ NUVA opened at $59.75 on Friday. The company has a quick ratio of 2.42, a current ratio of 3.99 and a debt-to-equity ratio of 1.11. NuVasive, Inc. has a 1-year low of $45.45 and a 1-year high of $72.61. The company has a fifty day moving average price of $53.64 and a 200 day moving average price of $54.23.
Several research analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of NuVasive in a research report on Wednesday. They issued a “buy” rating and a $65.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 target price on shares of NuVasive in a report on Thursday, March 24th. Morgan Stanley lowered their target price on shares of NuVasive from $62.00 to $60.00 and set an “equal weight” rating for the company in a report on Friday, January 7th. StockNews.com started coverage on shares of NuVasive in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Wells Fargo & Company started coverage on shares of NuVasive in a report on Monday, March 28th. They set an “overweight” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $64.25.
Hedge funds have recently modified their holdings of the company. Exchange Traded Concepts LLC raised its holdings in shares of NuVasive by 49.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 636 shares of the medical device company’s stock valued at $33,000 after purchasing an additional 210 shares during the period. Rockefeller Capital Management L.P. raised its holdings in shares of NuVasive by 35.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 1,926 shares of the medical device company’s stock valued at $115,000 after purchasing an additional 503 shares during the period. Point72 Hong Kong Ltd raised its holdings in shares of NuVasive by 3,406.6% in the 3rd quarter. Point72 Hong Kong Ltd now owns 2,139 shares of the medical device company’s stock valued at $128,000 after purchasing an additional 2,078 shares during the period. GSA Capital Partners LLP bought a new stake in shares of NuVasive in the 3rd quarter valued at about $219,000. Finally, Inspire Investing LLC bought a new stake in shares of NuVasive in the 3rd quarter valued at about $221,000. 98.06% of the stock is currently owned by institutional investors.
NuVasive Company Profile (Get Rating)
NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.
- Get a free copy of the StockNews.com research report on NuVasive (NUVA)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.